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Background: Peroxisome proliferator-activated receptor gamma (PPARG) is a 
nuclear factor that may act on the early development of ovarian follicles and on 
follicular steroidogenesis. However, the exact mechanism of PPARG action remains 
unknown. We have previously found that androgen excess alters early ovarian function 
and the PPARG system. The aim of the present study was to evaluate whether PPARG 
activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in 
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Methods: Female prepubertal rats were treated with equine chorionic 
gonadotropin (eCG) to induce folliculogenesis, together with dehydroepiandrosterone 
(DHEA) to induce hyperandrogenism and/or PGZ to evaluate PPARG activation. We 
assessed i) very early ovarian folliculogenesis, ii) PPARG activation, iii) ovarian 
steroidogenic enzymes, iv) the estradiol/testosterone ratio, v) the ovarian inflammatory 
status and vi) oxidative stress. 
Results: PGZ prevented the inactivation of ovarian PPARG induced by 
androgen excess by increasing PPARG itself and the gene expression of PPARG-
coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-
repressor (NCOR). PGZ also prevented the altered ovarian steroidogenesis, pro-
inflammatory status and oxidative stress induced by androgen excess.  
Conclusions: Our findings suggest that PPARG activation plays important 
roles in modulating early ovarian function, and highlight the importance of 
understanding the role(s) of PPARG activation in the ovary, and the possible 
involvement in the treatment of ovarian pathologies, and/or the impact in 
regulating/improving fertility.  
Key Words: PPARG, folliculogenesis, dehydroepiandrosterone, ovarian 
function, pioglitazone. 
Introduction 
Reproductive function is associated with energy balance [1, 2]. In the ovary, 
the nutritional status modulates ovarian function, [1] and several candidates have been 
involved as possible links between the nutritional status and the function of the different 
ovarian cells [3]. Some of these energy sensors are the peroxisome proliferator-activated 
receptors (PPARs), which are transcriptional factors belonging to the steroid receptor 
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PPARbeta/delta and PPARgamma) and described as key regulators of fatty acid and 
lipoprotein metabolism, glucose homeostasis, cellular proliferation/differentiation and 
the immune response [4, 5]. In the ovary, PPARgamma (PPARG) senses the nutritional 
status in the follicle [6] and may act in the development of follicles and their ability to 
support normal oocyte maturation (reviewed in [7]). The activation of PPARG by both 
endogenous and synthetic ligands modulates its transcriptional activity by increasing the 
recruitment of co-activators, such as PPARG co-activator 1 alpha (PGC1A) [8], and 
increasing the clearance of repressors such as the nuclear corepressor (NCOR), which 
down-regulates the transcriptional activity of PPARG [9]. In the ovary, upon activation, 
PPARG modulates ovarian steroidogenesis and cellular proliferation [6, 10], and its 
disruption leads to female subfertility [11]. However, the exact mechanism involved in 
PPARG activation remains unknown, particularly during early ovarian function.  
We have previously shown that the administration of a follicle stimulating 
hormone (FSH) analog promotes early follicular development in prepubertal rats [12]. 
In this window of development, exposure to androgen excess induces alterations in the 
ovarian function and related endocrine parameters [12, 13]. Androgen excess disturbs 
ovarian follicular development, leading to chronic anovulation, as observed in 
polycystic ovary syndrome (PCOS), a condition in which impaired follicular growth 
lead to menstrual disturbances and anovulatory infertility [14, 15]. Moreover, evidence 
indicates that prenatal or pre-pubertal androgen excess may be involved in the 
pathophysiology of PCOS [16, 17]. It has been reported PPARG activators, such as 
pioglitazone (PGZ) and rosiglitazone, improves the androgenic status and ovarian 
function [15]. However, the clinical use of these activators goes beyond the knowledge 
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Our murine model consists in a very short-term treatment of immature female 
animals with two hormones: equine chorionic gonadotropin (eCG), an efficient 
interspecies inducer of follicular recruitment [18], and dehydroepiandrosterone 
(DHEA), which promotes a hyperandrogenic condition [12]. Our previous results 
showed that DHEA treatment induces alterations in the very early ovarian function, 
along with a down-regulation of the PPARG system [12, 19]. Based on these previous 
findings, in the present study, we aimed to investigate whether the activation of the 
PPARG system, by the synthetic ligand PGZ, was able to prevent the alterations 
induced by androgen treatment. Specifically, we studied the role of PGZ in preventing 
the adverse effects of androgen excess on i) very early ovarian folliculogenesis, ii) 
PPARG activation, iii) ovarian steroidogenesis, iv) the estradiol2 (E2)/testosterone (T) 
ratio, v) Ovarian inflammatory status and vi) oxidative stress. 
Materials and Methods 
Animal model  
Sprague-Dawley prepubertal female rats (22-25 days of age) were housed 
under controlled temperature and illumination and allowed free access to food and 
water. All procedures were conducted in accordance with The National Institutes of 
Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, 
revised 1978). We used prepubertal rats to avoid previous estrous cycles that may 
interfere with the results, and our choice is supported by the fact that prepubertal rats are 
widely used to study the effect of androgen excess administration on ovarian function 
[20-22]. In this model, we have previously assayed the effect of a single dose of eCG on 
prepubertal rats and we found that eCG treatment yield the peak of progesterone at 8h, 
after this time serum hormone decreases [19]. This finding is in agreement with other 
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we have previously found an acute effect of both eCG and DHEA in early stage of 
follicular development, as previously reported [12, 19]. A group of 25 rats were injected 
intraperitoneally (ip) with 25 IU of eCG (Novormon, Syntex SA) in saline solution 
(eCG group). eCG+DHEA or DHEA group consisted of 25 rats injected with eCG plus 
a sc injection of 60 mg/kg body weight of DHEA (Sigma-Aldrich, USA) in sesame oil. 
A third group of 25 rats were injected with eCG together with DHEA and then orally 
administered with 1 mg/kg body weight of PGZ (ELEA, Buenos Aires, Argentina) in 
water (eCG+DHEA+PGZ). Although the current treatments with thiazoldineniones are 
prolonged, Cox et al showed that the bioavailability in plasma after a single dose is 
rapidly seen within 24 hours [24], therefore we decided to test the effect of PGZ at 8h. 
To assess any effect of PGZ per se, a fourth group of 25 rats were ip injected with eCG 
together with orally administration of PGZ (eCG+PGZ). After 8 h of treatments, rats 
were anesthetized with CO2 and killed by decapitation. Ovarian tissue was removed 
and; a) immediately fixed in 4% (w/v) paraformaldehyde for morphological studies, or 
b) stored at -80°C for subsequent ovarian assays. Also, trunk blood was collected and 
serum was separated by centrifugation, and stored at -80°C for subsequent oxidative 
stress and sexual hormones assays.  
Ovarian morphology  
Histological serial sections were obtained as described before [12]. Sections 
were analyzed independently by three of the authors, and ovarian follicles were 
classified and quantified as primordial (PF), primary (PrF), secondary (SF), and antral 
(AF). PF were classified as those formed by an oocyte surrounded by a flattened layer 
of pre-granulosa cells; PrF were those with at least one cuboidal layer of granulosa cells 
(GCs); SF were those with more than one layer of cuboidal GCs and an incipient layer 
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surrounded zona pellucida, and a basal lamina between GCs and TCs. Follicular atresia 
was also quantified, and atretic follicles were defined as follicles with >5% of the GCs 
having pyknotic nuclei.  
qPCR analysis 
mRNA levels in ovarian tissue were measured by qPCR as described before 
[12].We evaluated PPARG, NCOR, PGC1A, steroidogenic acute regulatory protein 
(STAR), cytochrome P450-17A1 (CYP17), 3β-hydroxysteroid dehydrogenase 
(3BHSD), 17β-hydroxysteroid dehydrogenase (17BHSD), aromatase (CYP19), tumor 
necrosis factor alpha (TNFA) and cyclooxygenase 2 (COX2). The 2(-DeltaDelta CT) 
method was used to analyze the relative changes in gene expression. Results are 
expressed as arbitrary units, and the RPL32 gene was used as a reference. Primers are 
shown in Table 1. 
WB analysis  
Protein levels were measured by WB as described before [12]. Diluted primary 
antibodies of (1/100) PPARG (H-100, sc-7196), (1/200) STAR (FL-285, sc-25806) and 
(1/100) COX2 (H-62, sc-7951) (Santa Cruz Biotechnology, Inc., USA) were used. Data 
of protein loading was normalized by applying the protein βActin (1/500) (Sigma Co.). 
The experiment was independently repeated three times. Results are expressed as 
arbitrary units.  
Estradiol and testosterone radioimmunoassays.  
E2 and T levels were determined by specific RIAs as described before [25]. E2 
sensitivity was 5–10 pg/tube andT sensitivity was 25–1600 pg/tube. The intra-assay and 
inter-assay variations of T were 7.5 and 15.1% respectively, and the cross-reaction 
between T and DHEA was <0.01 pg. Results are expressed as pg/ml serum. 
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PGE content was determined by RIA as previously reported [26]. Sensitivities 
of these assays were 10 pg/tube for PGE. The cross-reactivity of PGE2α was 100% with 
PGE1 and <0.1% with other prostaglandins. Results are expressed as pg/μg protein. 
Protein concentration was determined by the Bradford assay (Bio-Rad). 
Determination of lipid peroxidation  
The method used in the present study, as described before [26], quantifies 
serum MDA as the product of lipid peroxidation that reacts with trichloroacetic acid–
thiobarbituric acid–HCl (TCA-TBA-HCL) (Sigma), yielding a red compound that 
absorbs at 535 nm. Results are expressed as content of MDA (nanomoles MDA 
formed/ml serum). 
Determination of glutathione content in serum 
Glutathione (GSH) was quantified in serum as previously described [27]. The 
reduced form of GSH comprises the bulk of cellular protein sulfhydryl groups. Results 
are expressed as μM GSH. 
Statistical analysis 
Statistical analyses were carried out with the GraphPad Prism 5.0 (GraphPad 
software, San Diego, USA). Data were analyzed by 2-way ANOVA to assess the effects 
and interactions of 2 independent variables, and multiple comparisons were achieved 
using the Bonferroni post-hoc test. Statistical significance was defined at p<0.05 
Results 
PGZ prevented the down-regulation of the ovarian PPARG system induced by 
DHEA 
PGZ (eCG+DHEA+PGZ) partially prevented the decrease in both mRNA and 
protein levels of PPARG induced by DHEA treatment (Fig. 1 A-B). Note: we quantified 
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PPARG2 isoforms, according to the supplier. PGZ also prevented the decrease in the 
mRNA levels of PCG1A and partially prevented the increase in the mRNA levels of 
NCOR, induced by DHEA treatment (Fig. 1C-D). No significant effects of PGZ per se 
(eCG+PGZ) were found on PPARG, PGC1A or NCOR levels, when comparing to the 
eCG group (Fig. 1 A-D). 
PGZ treatment and ovarian morphology  
No preovulatory follicles or corpora lutea were observed in any of the 
treatment groups, an expected result considering the short age of the prepubertal rats. 
No differences in total ovarian weight were found between groups (data not shown). 
The percentage of PF was higher whereas that of PrF was lower in the DHEA 
treatment group than in the eCG group (Fig. 2A). PGZ partially prevented the 
alterations caused by the DHEA treatment, since the percentages of PF and PrF were 
similar to those in the DHEA treatment and eCG groups (Fig. 2A). In the PGZ per se 
group, we found no differences in the percentages of SF and AF in any of the treatment 
groups (Fig. 2A), or in any follicle class, comparing to the eCG group (Fig. 2A). The 
percentage of atresia was similar in all the treatment groups (Fig. 2B). 
The activation of the PPARG system prevented the alterations induced by 
DHEA in the levels of ovarian steroidogenic enzymes 
PGZ prevented the DHEA-induced increase in both the mRNA and protein 
levels of STAR (Fig. 3A-B), and the DHEA-induced increase in the mRNA levels of 
CYP17 (Fig. 3C), 3BHSD (Fig. 3D) and 17BHSD (Fig. 3E). To evaluate the balance in 
the synthesis of E2 and T, we assessed the mRNA levels of the aromatase CYP19. We 
found that PGZ prevented the DHEA-induced decrease in the mRNA levels of CYP19. 
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in the levels of STAR, 3β-HSD, 17β-HSD or CYP19, comparing to the eCG group (Fig. 
3C-F). 
The activation of the PPARG system prevented the alterations caused by 
DHEA in the E2/T ratio  
PGZ increased the serum levels of E2 and decreased those of T (Fig. 4A and B) 
as compared with the DHEA treatment group, thus leading the E2/T ratio to levels 
similar to those of the eCG group (Fig. 4C). PGZ per se did not alter systemic E2, T or 
E2/T ratio as compared with the eCG group (Fig. 4A-B).  
The activation of the PPARG system prevented the ovarian pro-inflammatory 
status induced by DHEA 
PGZ prevented the DHEA-induced increase in mRNA levels of TNFA, an 
early inflammatory marker (Fig. 5A), and both the mRNA and protein levels of COX2 
(Fig. 5B-C). Moreover, PGZ decreased the levels of PGE, comparing to the DHEA 
treatment, to values even lower than those observed in the eCG group (Fig. 5B-D). In 
addition, PGZ per se did not alter the protein or mRNA levels of COX2, mRNA levels 
of TNFA, or PGE content, comparing with the eCG group (Fig. 5C). 
The activation of the PPARG system exerted a protective effect against DHEA-
induced oxidative stress 
PGZ prevented the DHEA-induced alterations in the systemic 
oxidant/antioxidant balance evaluated by MDA and GSH (Fig. 6A-B). We found no 
effect per se of PGZ on serum MDA or GSH levels, as compared with those of the eCG 
group (Fig. 6A and B). 
Discussion 
In previous studies, we found that androgens alter early ovarian function, 
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status, and decrease the activation of PPARG in the ovary [12, 19]. In agreement with 
these results, it has been shown an association between PPARG and androgen excess 
disorders like PCOS [28-30].  
Here, we showed that PGZ activated PPARG through the modulation of 
PPARG itself and the gene expression of co-regulators PGC1A and NCOR. These data 
are in agreement with previous findings showing that PGZ increases the gene 
expression of the co-activator PGC1A [31] and promotes the clearance of NCOR [9]. 
Despite the complexity of the transcriptional mechanism of PPARG [7], this is the first 
time that PGZ has been shown to activate PPARG through its own expression and the 
gene expression of PGC1A and NCOR, during early ovarian function. 
It has been found that gonadotropins, together with intraovarian regulators, 
have a stimulatory effect on early folliculogenesis [32]. Thus, we induced early ovarian 
development in prepubertal rats by means of an eCG injection. In that context, when 
follicular stimulation was induced in the presence of androgen excess, the percentage of 
PF increased while that of PrF decreased. These data are in agreement with the evidence 
that androgens are involved in early follicular recruitment [32, 33]. Furthermore, we did 
not find an altered percentage of atretic follicles in the presence of androgen excess, in 
agreement with Vendola et al [33], and we suggest that, at least in the short term, 
androgens are not atretogenic. These findings are consistent with that observed in  
women with PCOS [34], who show prolonged survival of preantral follicles with 
respect to normal-cycling women, in which preantral follicles either grow rapidly to 
become dominant follicles or collapse in atresia. However, if the exposure to androgen 
excess continued, follicles with abnormal growth would eventually collapse back into 
the ovarian stroma, leading to the stromal hypertrophy typical of PCOS and chronic 
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prevented the alterations induced by the excess of androgens, since PGZ restored the 
percentages of both PF and PrF to gonadotropin-induced values. These findings support 
the notion that PPARG plays a role in the early stages of follicular development [6, 7].  
PPARG system modulates the expression of genes involved in follicular 
development, ovulation, oocyte maturation, and corpus luteum development [6, 10]; 
however, this is the first time that it is shown that PPARG activation prevents the 
deregulation of steroidogenic pathway enzymes induced by androgen excess. In fact, 
PPARG activation prevented the alteration in the estrogens/androgens ratio, by means 
of modulating the gene expression of steroidogenic enzymes, especially by increasing 
the gene expression of aromatase CYP19, the enzyme that synthesizes E2 from T. The 
consequence of this action is the restoration of the E2/T ratio to gonadotropin-induced 
values. An abnormal E2/T ratio contributes to the poor oocyte quality observed in 
prenatally hyperandrogenized female rhesus monkeys, sheep and rats [17] and also in 
women with PCOS [36]. A balanced E2/T ratio is essential during follicular 
development to promote the dominant follicle [37] and this could explain why women 
with PCOS are unable to produce an ovulatory follicle. Moreover, the re-establishment 
of the E2/T ratio by PPARG activation could also explain the prevention of the 
alterations in PF and PrF described above.   
In normal conditions, a pro-inflammatory status is established just before 
ovulation occurs, which correlates with a down-regulation of the PPARG system [7]. In 
addition, the gene expression of COX2, the rate limiting enzyme of PG synthesis, is low 
in the early stages of folliculogenesis and is high prior to ovulation [38]. Here we 
showed that activation of PPARG decreased the pro-inflammatory status induced by 
androgen excess (by the decrease in the gene and protein expression of COX2, PGE 











PPARG and ovarian function in DHEA-treated rats 
 
12 
PPARG exerts an anti-inflammatory effect, as shown by other authors [39, 40]. 
Moreover, an anti-inflammatory status results favorable during the early stages of 
ovarian folliculogenesis [41]. In summary, the modulation of the inflammatory process 
by PGZ induces a favorable early ovarian environment necessary for the establishment 
of the future dominant follicle.  
Systemic oxidative stress may be related to the ovarian pro-inflammatory status 
found in this study in the presence of androgen excess, since an increase of TNFA, 
COX2 and PGE is involved in the generation of systemic free radicals and subsequent 
oxidative stress [42]. Here, we demonstrated that PPARG activation was able to prevent 
the circulating oxidative stress, in agreement with other authors, who have indicated 
that PPARG can exert a protective effect against oxidative stress [40], decreasing the 
generation of free radicals [43]  and increasing the antioxidant metabolite GSH [44]. 
One question that remains to be answered is the effect of PGZ per se treatment. 
It has been described thiazoldineniones effects in the ovary independent of PPARG 
activation [7]. In the present study, we found activation of ovarian PPARG by PGZ only 
in the presence of androgen excess, and not in the PGZ per se treatment. The only PGZ 
per se effect was the down-regulation of the gene expression of steroidogenic enzyme 
CYP17. The same effect of PGZ independent of PPARG activation has been observed 
in a human model of adrenal steroidogenesis, where PGZ, and not rosiglitazone, 
downregulated CYP17 expression [45]. Further studies are necessary to discern the 
mechanism of action of PGZ dependent and independent of PPARG activation in the 
early ovarian function. In addition, it is important to point out that  the PPARs have 
been shown to coordinately regulate the expression of genes including those that control 
fatty acid and lipoprotein metabolism, glucose homeostasis, cellular proliferation/ 
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roles in the treatment of endocrine disorders: PPARG ligands are effective in treating 
insulin resistance and T2DM patients, PPARalpha agonists provides anti-dyslipidemic 
and anti-atherosclerotic outcomes, and recent findings indicate that PPARdelta ligands 
have beneficial effects on circulating lipids and obesity (reviewed in [46-48]). 
Taken together, our results demonstrate that the activation of PPARG by PGZ 
prevents the alterations caused by androgen excess in the early ovarian function. 
Moreover, this is the first study showing evidence of this very early molecular 
mechanism of PPARG activation and reveals the importance of its activation during the 
early stages of follicular development. However, the precise role of PPARG in the 
ovary in both physiological and pathological conditions remains to be fully elucidated. 
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Legends and tables 
Figure 1: Expression PPARG, PGC1 and NCOR. Relative levels of: mRNA 
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Relative levels of: mRNA for PGC1A (C) and NCOR (D). The columns represent the 
mean values ± SEM. (N=5 replicates per group). *p<0.05 **p<0.01 compared with the 
eCG group. #p< 0.05 comparing eCG+DHEA vs. eCG+DHEA+PGZ groups. NS: not 
significant. 
Figure 2: Ovarian morphology. A) Percentages of the different types of 
ovarian follicles present in the ovaries. Statistical differences were assessed between 
treatments within each class of follicle (C) Percentage of atretic follicles present in 
ovaries. The columns represent the mean values ± SEM. (N= 5 replicates per group). 
*p< 0.05 compared with the eCG group. NS: not significant. 
Figure 3: Expression of ovarian steroidogenic enzymes. Relative levels of: 
mRNA (A) and proteins (B) of STAR. A representative WB of STAR is shown in (B). 
Relative levels of mRNA for CYP17 (C), 3BHSD (D), 17BHSD (E) and CYP19 (F). 
The columns represent the mean values ± SEM. (N=5 replicates per group). *p< 0.05 
**p<0.01 and ***p<0.001, compared with the eCG group. #p<0.05, ##p<0.01 and 
###p<0.001, comparing eCG+DHEA vs. eCG+DHEA+PGZ groups. NS: not significant. 
Figure 4: T, E2 and E2/T ratio. Serum levels of T (A) and E2 (B). E2/T ratio is 
shown in (C). Each column represents the mean values ± SE.M. (N=5 replicates per 
group) *p<0.05 and **p<0.01, compared with the eCG group. #p<0.05, ##p<0.01 and 
###p<0.001, comparing eCG+DHEA vs. eCG+DHEA+PGZ groups. NS: not significant. 
Figure 5: Expression of ovarian inflammatory markers. (A) Relative levels of 
mRNA of cyclooxygenase 2 (COX2). (B) A representative WB of COX2 (D) Relative 
levels of COX2 protein (E) Ovarian content of prostaglandin E (PGE). Each column 
represents the mean values ± SEM (N=5 replicates per group) *p<0.05 compared with 
the eCG group. ##p<0.01 and ###p<0.001, comparing eCG+DHEA vs. 
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Figure 6: Oxidative stress in serum. Levels of MDA (A) and GSH (B). Each 
column represents the mean values ± SEM. (N=5 replicates per group) *p<0.05 and 
**p<0.01, compared with the eCG group. #p<0.05 comparing eCG+DHEA vs. 














































Table 1: List of primers used in qPCR 
 
 
Gene Primer Forward (5’ – 3’) Primer Reverse (5’ – 3’) 
Pparg TTTTCAAGGGTGCCAGTTTC GAGGCCAGCATGGTGTAGAT 
Ncor TATCGGAGCCATCTTCCCAC ACTTGGGTATCCTGGGGTTG 
Pgc1a AATGCAGCGGTCTTAGCACT GTGTGAGGAGGGTCATCGTT 
Star GCAGGGGGATTTCTGAATTT GTCTCCGTCTCTGTGGCTTC 
Cyp17a TCTCATTACACCCACGCAGA CGGGGCAGTTGTTTATCATC 
3bhsd GACACCCCTCACCAAAGCTA TTGTAAAATGGACGCAGCAG 
17bhsd TCTCATTACACCCACGCAGA CGGGGCAGTTGTTTATCATC 
Cyp19a CCTGGCAAGCACTCCTTATC CCACGTCTCTCAGCGAAAAT 
Tnfa TCCCAGAAAAGCAAGCAACC TAGACAGAAGAGCGTGGTGG 
Cox2 ATGAGTACCGCAAACGCTTC CCCCAAAGATAGCATCTGGA 
Rpl32 TGGTCCACAATGTCAAGG CAAAACAGGCACACAAGC 
AC
CE
PT
ED
 M
NU
SC
RI
PT
